Artelo Biosciences (ARTL) director granted stock options for 292 shares

Rhea-AI Filing Summary

Artelo Biosciences director Kelly Steven received a new stock option grant. On January 30, 2026, Steven was awarded stock options to purchase 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, with no purchase price for the option itself.

The options vest in full if Steven continues as a service provider until the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the company’s next annual stockholder meeting after that date. After this grant, Steven beneficially owns 292 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Steven

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.71	01/30/2026		A		292		(1)	01/30/2036	Common Stock	292	$0.00	292	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ARTL director Kelly Steven report on this Form 4?

Kelly Steven reported receiving a grant of stock options for 292 shares of Artelo Biosciences common stock. The options are a right to buy shares in the future, rather than an immediate stock purchase or sale, and are held directly by Steven.

What are the key terms of Kelly Steven’s ARTL stock options granted on January 30, 2026?

The options allow purchase of 292 Artelo Biosciences common shares at an exercise price of $1.71 per share. The option itself was granted at a price of $0.00, reflecting a typical compensatory equity award structure rather than a market transaction for cash.

How and when do Kelly Steven’s Artelo Biosciences options vest?

All 292 option shares vest 100% if Steven remains a service provider through vesting. Vesting occurs on the earlier of the one-year anniversary of January 30, 2026, or the day before the next annual stockholders’ meeting following that vesting commencement date.

How many derivative securities does Kelly Steven own in ARTL after this transaction?

Following the January 30, 2026 grant, Kelly Steven beneficially owns 292 derivative securities, all from this stock option award. These represent the right to acquire 292 shares of Artelo Biosciences common stock, subject to vesting and payment of the $1.71 exercise price.

Is the January 30, 2026 ARTL Form 4 a stock sale by Kelly Steven?

No. The Form 4 reports an acquisition of stock options, not a sale of common shares. Steven received compensatory options with a future exercise right, and there is no indication of any disposition of existing Artelo Biosciences stock in this filing.

What is Kelly Steven’s relationship to Artelo Biosciences mentioned in this Form 4?

The filing identifies Kelly Steven as a director of Artelo Biosciences, Inc. The vesting of the options depends on Steven continuing as a “Service Provider” under the company’s equity plan through the specified vesting date conditions in the award’s footnote.